Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
Holding RGNX?
Track your performance easily
RGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.56 - $28.80
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.76M
Market Cap
$354.25M
Enterprise Value$423.24M
Total Cash (Recent Filing)$89.55M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 04, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding49,545,070
10 Day Avg. Volume1,420,391
30 Day Avg. Volume1,755,002
Standard Deviation0.17
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.20
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue5.02
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$34.70Price Target Upside370.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
RegenXBio News
PremiumCompany Announcements
RegenXBio Partners with Nippon Shinyaku on Gene Therapies
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsPositive phase 1/2 functional data from RGX-202 for DMD puts RegenXBio on competitive footing with Elevidys.
Financial MilestonesRegenXBio Inc. has entered a strategic partnership with Nippon Shinyaku for the commercialization of RGX-121 and RGX-111 in the US and Asia, potentially bringing up to $810 million in milestones and royalties.
Strategic PartnershipREGENXBIO announced a strategic partnership with Nippon Shinyaku for the development and commercialization of RGX-121 and RGX-111 in the U.S. and Asia.
Bears Say
Clinical Delivery ChallengesSubretinal delivery may limit commercial uptake and suprachoroidal delivery data presented to date is still early.
Efficacy And Treatment BurdenThe efficacy of suprachoroidal RGX-314 appears to be numerically lower than competitors, and the need for steroid prophylaxis implies potential additional burden for patients and clinicians.
Sales ProjectionsProjected peak sales of RGX-202 are toned down.
---
Ownership Overview
9.27% Insiders
18.42% Mutual Funds
2.16% Other Institutional Investors
53.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $6.56 and its highest was $28.80 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $354.25M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Mar 04, 2025 which is in 42 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Nov 06, 2024. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of -$1.122 by -$0.048.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.13.
How many shares outstanding does RegenXBio have?
RegenXBio has 49,545,070 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.17 in its last earnings report, missing expectations of -$1.122. Following the earnings report the stock price went up 18.664%.
Which hedge fund is a major shareholder of RegenXBio?
Among the largest hedge funds holding RegenXBio’s share is Moore Capital Management LP. It holds RegenXBio’s shares valued at 1M.
---
RegenXBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.70 (370.83% Upside)
$34.70 (370.83% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 82.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.95%
12-Months-Change
Fundamentals
Return on Equity
-71.87%
Trailing 12-Months
Asset Growth
-18.09%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
---
RGNX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in REGENXBIO's gene therapy programs with upcoming milestones, indicating strong progress in the pipeline. However, there were decreases in R&D expenses and cash, reflecting some financial challenges.Read More>---
RGNX Stock 12 Month Forecast
Average Price Target
$34.70
▲(370.83% Upside)
Technical Analysis
Adverum Biotechnologies
―
Abeona Therapeutics
―
Krystal Biotech
―
uniQure
―
Intellia Therapeutics
―
Bluebird Bio
―
Best Analysts Covering RGNX
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-18.23%
assigned a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -18.23% per trade.
---